OSCR

The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest, while groundbreaking AI applications help enhance and accelerate the drug discovery process. On top of that, potential mergers and acquisitions activity, as big pharmaceutical companies face a major patent cliff, could provide opportunities for new firms to stand out.

WOOF, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 25th, 2026.

Oscar Health's profit rebound faces a test as rising medical spending and a larger member base threaten second-half profitability.

Oscar Health (OSCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OSCR, SNDR and TFII made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 23rd, 2026.

Oscar Health is upgraded to Strong Buy with a new $45 fair value, reflecting raised 2026–2029 earnings targets and an expanded TAM. Management projects 2029 EPS of $4+ and 2026 operating earnings of $600–800M, driven by ACA execution, CHOICE, and Lucie marketplace growth. CHOICE and Lucie expand OSCR's addressable market by 65%, with revenue estimates rising from $18.85B in 2026 to $32.6B in 2029.

LCUT, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 23rd, 2026.

Insurance stocks can be well positioned in a higher interest rate environment, particularly because insurers collect premiums upfront and invest that money until claims are paid.

Oscar Health, Inc. (OSCR) closed the most recent trading day at $31.29, moving 2.61% from the previous trading session.

WOOF, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 21st, 2026.